|Day Low/High||132.10 / 134.25|
|52 Wk Low/High||121.00 / 148.99|
I spent a lot of time on the (respectful) Rosenberg/Kass debate on economic growth and interest rates today: * And Now A Word From Dennis Rosenberg * And Now A Word From Dennis Rosenberg (Part Deux) * And the Rosenberg Empire Strikes Again * Ju...
Despite a long list of negatives, the ursine class has been unable to push the market into a full-blown downtrend.
Stocks closed lower after digesting mixed first quarter earnings data.
"It is always by way of pain one arrives at pleasure." - Marquis de Sade Today's Dow Jones decline is the worst since March 21, 2017 -- pulled down materially by weakness in Johnson & Johnson and Goldman Sachs . Stocks are down for the fourth day ...
Stock extend losses as Goldman Sachs and Johnson & Johnson lead the Dow lower.
I'm keeping an eye out, but there isn't enough support to suggest that now is the time to start buying.
Apple's reported move into bio sensors could lead to even greater heights.
Repatriation of profits would bring in money and tax revenue.
Your round-up of the financial news from around the world.
Goldman Sachs and Bank of America release earnings on Tuesday.
These four stocks are showing short-term gain catalysts and longer-term growth potential.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...
It's pretty normal to have profit-taking after such a strong first quarter.
We know that we are in the era when index managers are ascendant.
Weaker dollar may not be bad for Boeing, Johnson & Johnson and Procter & Gamble.
Let me teach you how to Dougie. Consumer confidence is a coincident/lagging indicator. And excitement over the print, is (quite frankly) "first level thinking." As support, check out these two charts of the day -- it's "second level thinking." Snap ...
Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.
The GOP is scrambling for votes on Obamacare Repeal.
"I had nothing to offer anybody except my own confusion." -- Jack Kerouac So, color me confused. But I will persevere and write "Takeaways!" While a lot didn't make sense, I suspect many traders/investors were caught "offsides." Peter Boockvar do...
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
There are nearly too many surging sectors to count.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
It's better to be early than wrong. Though being wrong isn't so awful.
Icahn may have a tough time finding interest in this behemoth.